Immunology
Our goal is to improve the diagnosis of immune-mediated inflammatory diseases, improve patients’ access to the best possible treatments and continue to provide new and better medicines.
Our breakthroughs have changed the lives of millions of people around the world living with some of the most common immune-mediated inflammatory diseases.
We invest heavily in continuous medical education of doctors and care providers, uniting different therapeutic areas to share expertise and best practices.
Even though we have made great progress in the last decade for the treatment of immune-mediated inflammatory diseases, our work aims to raise the bar to make periods of disease remission more durable and allow patients with these debilitating diseases to lead normal lives.”
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
You are now leaving J&J Innovative Medicine EMEA
We inform you that the privacy policy at the remote site can be different from J&J Innovative Medicine EMEA. Click continue to proceed.
References
[1] Lofvendahl, S., et al. Incremental costs for psoriasis and psoriatic arthritis in a population-based cohort in southern Sweden: is it all psoriasis-attributable morbidity? Journal of Rheumatology, 2016;43(3):640-647
[2] Lonffors, S., et al. IBD and health-related quality of life - discovering the true impact. Journal of Crohn’s and Colitis, 2014;8:1281-1286
[3] Najafi, S., et al. The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach. Clin Rheumatol, 2020;39:3223–3235
[4] Eghlileb, A.M., et al. Psoriasis has a major secondary impact on the lives of family members and partners. Br J Dermatol, 2007;156(6):1245-50
[5] Dibley, L., et al. The experience of stigma in inflammatory bowel disease: An interpretive (hermeneutic) phenomenological study. J Adv Nurs, 2018;74:838-851
[6] Ograczyk, A., et al. Itch, disease coping strategies and quality of life in psoriasis patients. Postepy Dermatologi Alergologii, 2014;5:299-304
[7] Narayanan, S., et al. 2014. Disease burden and patient reported outcomes among patients with moderate to severe psoriasis: an ethnography study. Psoriasis (Auckl), 2014;5:1-7
[8] Cooper, G.S., et al. Recent Insights in the Epidemiology of Autoimmune Diseases: Improved Prevalence Estimates and Understanding of Clustering of Diseases. J Autoimmun. 2009;33(3-4):197-207
[9] Mease P. Assessing impact of Psoriatic Arthritis on Patient Function and Quality of Life: Lessons Learned from Other Rheumatologic Conditions. Semin Arthritis Rheum, 2009;38(4):320-335
[10] Walker, J., Littlejohn, G. Measuring quality of life in Rheumatic conditions. Clin Rheumatol, 2017; 26,p:671-673
[11] Lupus Foundation of America. Lupus facts and statistics. 2016. Available at:
https://www.lupus.org/resources/lupus-facts-and-statistics. Accessed: October 2022
[12] Scotti, L., et al. Prevalence and incidence of psoriatic arthritis: a systematic review and meta-analysis. Semin Arth Rheum. 2018;48:28-34
[13] Bacconier, L., et al. Psychological distress over time in early rheumatoid arthritis: results from a longitudinal study in an early arthritis cohort. Rheumatology (Oxford) 2015;54(3):520-7
[14] Pompili, M., et al. Suicide risk and psychiatric comorbidity in patients with psoriasis. J Int Med Res. 2016;44(IS):61-66
[15] Amador-Patarroyo. M.J., et al. How does age at onset influence the outcome of autoimmune diseases? Autoimmune Dis, 2012;251730
[16] Habibi, F., et al. Quality of life in inflammatory bowel disease patients: A cross-sectional study. J Res Med Sci, 2017;22:104
[17] Becker, H.M., et al. Living with inflammatory bowel disease: A Crohn’s and Colitis Canada survey. Can J Gastroenterol Hepatol, 2015;29(2):77-84
[18] Shah, K., et al. Real-world burden of comorbidities in US patients with psoriatic arthritis. RMD Open, 2017;3(2):3
[19] Bernstein, C.N., et al. Increased Burden of Psychiatric Disorders in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25(2):360-368
[20] Liu JK. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg (Lond). 2014;3(4):113-116
[21] EFCCA. My IBD Journey – animation series. 2019. Available at:
https://efcca.org/projects/my-ibd-journey-animation-series. Accessed: October 2022
CP-459038
September 2024